Diabetes

The FDA has approved the AstraZeneca once-weekly injectable therapy for use in children aged 10 to 17 years.

At the virtual Scientific Sessions for the American Diabetes Association, Jennifer Sherr, MD, discussed the findings of a study of the Omnipod 5 automated insulin delivery system in very young children with type 1 diabetes.

An oral abstract presentation at the American Diabetes Association Virtual 81st Scientific Sessions highlighted a cardioprotective benefit of sodium-glucose co-transporter-2 inhibitors.

At the virtual Scientific Sessions for the American Diabetes Association, a study shows that metformin can improve adolescent type 1 diabetes.

A study presented at the American Diabetes Association Virtual 81st Scientific Sessions compared flash glucose monitoring with self-monitoring of blood glucose in patients with diabetes and moderate-to-advanced chronic kidney disease.

A study presented at the American Diabetes Association Virtual 81st Scientific Sessions evaluated metformin prescribing for patients with type 2 diabetes and chronic kidney disease.

A poster presented at the American Diabetes Association Virtual 81st Scientific Sessions highlighted the effect of a physician-pharmacist collaborative management team in diabetes preventative care services.

A study presented during a poster session at the American Diabetes Association Virtual 81st Scientific Sessions evaluated performance, safety, and satisfaction of an extended-wear insulin infusion set in patients with type 1 diabetes.

A session from the 2021 PQA Annual Meeting highlighted the benefits of virtual outreach in advancing patient care amid the COVID-19 pandemic and beyond.

Individuals with prediabetes may be at increased risk of suffering an adverse cardiovascular event.

A session at the 2021 Pharmacy Quality Alliance Meeting explored the results of Walgreens’ recent initiatives focused on addressing social determinants of health.

Technology and mobile health apps can be valuable tools in diabetes management.

Dapagliflozin (Farxiga; AstraZeneca) is the first SGLT2 inhibitor approved for the treatment of chronic kidney disease regardless of diabetes status.

A session held during the American Pharmacists Association 2021 Annual Meeting and Exposition provided an update on diabetes practice changes and new treatments.

Dasiglucagon (Zegalogue; Zealand Pharma) showed clear clinical benefit in median time to blood glucose recovery, according to 3 clinical trials.

Once-weekly semaglutide 2.4 mg resulted in sustained reductions in weight for those who are overweight or obese, the investigators reported.

Insulin resistance and type 2 diabetes were major contributors to premature coronary heart disease, according to the study results.

Pharmacists can help patients through education, therapy, and lifestyle modifications.

The latest Heart Disease and Stroke Statistical Update highlighted pandemic-related trends that may impact cardiovascular disease mortality for years.

A recent study examined patient characteristics and factors affecting COVID-19 mortality in individuals with diabetes.

A recent study examined how insulin levels and body mass index may have ties to mental health concerns.

Investigators compared outcomes among patients with COVID-19 and hypertension through modifying blood pressure medication use.

Over-the-counter product selection for patients with diabetes.

The agency granted priority review to dapagliflozin (Farxiga; AstraZeneca) for the treatment of new or worsening chronic kidney disease in adults with and without type 2 diabetes.

The Drug Topics® team rounded up some of our top-read articles from the last year.

A study to be presented at the annual meeting of the Radiological Society of North America reported that COVID-19 patients with diabetes and hypertension may have a higher risk for neurologic complications.

What pharmacists need to know about helping patients navigate changing landscape.

Researchers reported that patients who received finerenone had a lower risk of kidney failure or death from renal causes.

A subgroup analysis of the DAPA-CKD phase 3 trial reported on the continued benefit of dapagliflozin in patients with chronic kidney disease, regardless of underlying cause.

Patients now have a variety of options to help them lose weight, and pharmacists can offer a variety of specialized services to support their patients’ needs.